Abstract A44: Clinical value of immunohistochemical expression of EGFL7 within high-grade serous ovarian cancer tissue

Autor: Jacek J. Sznurkowski, Anton Zawrocki, Maciej Pawlowski
Rok vydání: 2016
Předmět:
Zdroj: Clinical Cancer Research. 22:A44-A44
ISSN: 1557-3265
1078-0432
DOI: 10.1158/1557-3265.ovca15-a44
Popis: Epidermal growth factor like domain 7 (Egfl7) is expressed by endothelial cells in normal tissues and by malignant cells in various human tumors. Aim: to analyze patterns of immunohistochemical (IHC) staining of Egfl7 within high grade serous ovarian cancer (HGSOC) tissue and to assess clinical value of this biomarker. Material and methods: The IHC staining and pathological analyses were performed on paraffin-embedded primary tumours collected from 73 HGSOC patients with verified clinical history. Mouse anti-human monoclonal antibody against Egfl7, was used. Egfl7 expressing tumors were classified qualitatively in accordance to intense of staining (HSCORE). The appropriate statistical analyses were performed. P-values of Results: Egfl7 was expressed by the cancer cells within 63 of 73 primary HGSOC tumors (68.3%). Endothelial expression of this biomarker was sporadic. Cancer cells presented two patterns of staining: cytoplasmic only in 50/72 cases (69.4%) and nuclear/cytoplasmic in 13/72 cases (18%). Median duration of the follow-up was 47.25 months (range 17–79 months) Cytoplasmic expression of Egfl7 was not correlated with any of clinico-pathological features as well as with prognosis. The presence of nuclear/cytoplasmic staining within HGSOC predicts worse response for chemotherapy and correlates with increased preoperative levels of CA125. Conclusion: Cancer endogenous expression of Egfl7 is frequent within HGSOC tissue. Predictive value of nuclear/cytoplasmic staining of Egfl7 for chemoresistance should be further evaluated. Citation Format: Jacek Jan Sznurkowski, Anton Zawrocki, Maciej Pawlowski. Clinical value of immunohistochemical expression of EGFL7 within high-grade serous ovarian cancer tissue. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr A44.
Databáze: OpenAIRE
Externí odkaz: